Clinical Trials Logo

Intractable Cancer clinical trials

View clinical trials related to Intractable Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04695223 Recruiting - Refractory Cancer Clinical Trials

Arsenic Trioxide for Structural p53 Mutations

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

TP53 is the most frequently mutated gene in cancer, but these mutations remain therapeutically non-actionable. Previous study reported arsenic trioxide could rescue structural p53 mutations, endowing p53 mutations with thermostability and transcriptional activity. Under Vivo and Vitro experiments, arsenic trioxide could reactivate mutated p53 to inhibit tumor. This trial aimed to explore the efficacy and safety of arsenic trioxide in refractory cancer patients with structural p53 mutations.